<table>
<thead>
<tr>
<th>A Clinical Guideline for the Management of Hyperkalaemia in Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>For Use in:</strong></td>
</tr>
<tr>
<td><strong>By:</strong></td>
</tr>
<tr>
<td><strong>For:</strong></td>
</tr>
<tr>
<td><strong>Division responsible for document:</strong></td>
</tr>
<tr>
<td><strong>Key words:</strong></td>
</tr>
<tr>
<td><strong>Name of document author:</strong></td>
</tr>
<tr>
<td><strong>Job title of document author:</strong></td>
</tr>
<tr>
<td><strong>Name of document author’s Line Manager:</strong></td>
</tr>
<tr>
<td><strong>Job title of author’s Line Manager:</strong></td>
</tr>
<tr>
<td><strong>Supported by:</strong></td>
</tr>
<tr>
<td><strong>Assessed and approved by the:</strong></td>
</tr>
<tr>
<td><strong>If approved by committee or Governance Lead Chair’s Action; tick here ☑</strong></td>
</tr>
<tr>
<td><strong>Date of approval:</strong></td>
</tr>
<tr>
<td><strong>Ratified by or reported as approved to (if applicable):</strong></td>
</tr>
<tr>
<td><strong>To be reviewed before:</strong></td>
</tr>
<tr>
<td><strong>To be reviewed by:</strong></td>
</tr>
<tr>
<td><strong>Reference and / or Trust Docs ID No:</strong></td>
</tr>
<tr>
<td><strong>Version No:</strong></td>
</tr>
<tr>
<td><strong>Compliance links: (is there any NICE related to guidance)</strong></td>
</tr>
<tr>
<td><strong>If Yes - does the strategy/policy deviate from the recommendations of NICE? If so why?</strong></td>
</tr>
</tbody>
</table>
### Clinical Guideline for the Management of Hyperkalaemia in Adults

#### Version and Document Control:

<table>
<thead>
<tr>
<th>Version No.</th>
<th>Date of Update</th>
<th>Change Description</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>JCG0020 v1</td>
<td>31 July 2014</td>
<td>Change of header and reference to joint hospital version</td>
<td>THCGAP</td>
</tr>
<tr>
<td>JCG0020 v2</td>
<td>03 March 2017</td>
<td>Addition of an alternative insulin / glucose treatment option (8 units actrapid in 100mL 20% glucose)</td>
<td>Dr C Ross, Mr N Weavers</td>
</tr>
<tr>
<td>JCG0020 v3</td>
<td>01 October 2018</td>
<td>Change in dose of Calcium Gluconate. Advice on (K⁺) and (Glucose) monitoring.</td>
<td>Dr C Ross</td>
</tr>
<tr>
<td>CG9078 v4</td>
<td>30 June 2022</td>
<td>Change of trust template to newest version, change from joint clinical guideline to NNUHFT trust guideline Change in insulin/glucose treatment option based on renal association hyperkalaemia guideline Addition of sodium zirconium cyclosilicate</td>
<td>Dr R Varma Miss N Korn</td>
</tr>
<tr>
<td>CG9078v5</td>
<td>25 July 2023</td>
<td>Change in administration rate for calcium gluconate Change in monitoring frequency for potassium in moderate or severe hyperkalaemia</td>
<td>Dr R Varma Dr J Patrick Miss N Korn</td>
</tr>
</tbody>
</table>

---

**This is a Controlled Document**

Printed copies of this document may not be up to date. Please check the hospital intranet for the latest version and destroy all previous versions.
Clinical Guideline for the Management of Hyperkalaemia in Adults

Author/s: Dr R Varma, Nicola Korn
Author/s title: Specialist Register, Specialist Pharmacist
Approved by: Chair of CGAP
Date approved: 02/08/2023
Review date: 02/08/2024
Available via Trust Docs
Version: 5
Trust Docs ID: 9078
Page 3 of 14

Contents page
1. Quick Reference Guide Emergency Management of Hyperkalaemia in Adults..4
2. Objective/s ...........................................................................................................................................5
3. Scope..................................................................................................................................................5
4. Rationale............................................................................................................................................5
5. Causes of hyperkalaemia....................................................................................................................5
  5.1 Pseudohyperkalaemia........................................................................................................................5
  5.2 Excessive potassium intake..............................................................................................................5
  5.3 Re-distribution................................................................................................................................6
  5.4 Impaired renal potassium excretion................................................................................................6
6. Processes to be followed....................................................................................................................7
  6.1 Broad recommendations..................................................................................................................7
  6.2 STEP 1: Antagonism of cardiac effects:.........................................................................................8
    6.2.1 Calcium......................................................................................................................................8
  6.3 STEP 2: Redistribution of potassium into cells..............................................................................8
    6.3.1 Insulin and Glucose (off label use).............................................................................................8
    6.3.2 ß2-Adrenergic Agonists (Salbutamol) (off label use)..................................................................10
    6.3.3 Sodium bicarbonate..................................................................................................................10
  6.4 STEP 3: Removal of potassium from the body..............................................................................10
    6.4.1 Intravenous fluids.....................................................................................................................10
    6.4.2 Diuretics....................................................................................................................................11
      6.4.2.1 Sodium zirconium cyclosilicate..........................................................................................11
    6.4.3 Cation-exchange resins............................................................................................................11
    6.4.4 Extracorporeal potassium wasting – dialysis...........................................................................12
    6.4.5 Other measures........................................................................................................................12
7. Clinical audit standards.....................................................................................................................13
8. Summary of development and consultation process undertaken before registration and dissemination..................................................................................................................13
9. References.........................................................................................................................................13
10. Equality Impact Assessment (EIA)..............................................................................................14
1. **Quick Reference Guide Emergency Management of Hyperkalaemia in Adults**

- Assess patient using ABCDE approach
- 12-lead ECG and monitor cardiac rhythm if serum K ≥ 6.0 mmol/L
- Exclude pseudohyperkalaemia
- Give empirical treatment for arrhythmia if hyperkalaemia suspected
- Repeat U&Es, request CK if rhabdomyolysis is suspected
- Review / stop any drugs that may be contributing to hyperkalaemia

**MILD**

K⁺ 5.5 – 5.9 mmol/L

Consider cause and need for treatment

**MODERATE**

K⁺ 6.0 – 6.4 mmol/L

Treatment guided by clinical condition, ECG and rate of rise

ECG Changes?  
For patients in cardiac arrest follow ALS algorithm
- Peaked T waves
- Broad QRS
- Bradycardia
- Flat / absent P waves
- Sine wave
- VT

**SEVERE**

K⁺ ≥ 6.5 mmol/L

Emergency treatment indicated, seek expert help

- 30 mL 10 % Calcium gluconate IV
  - use large IV access & administer over 10 min
  - administer over 30 minutes if on Digoxin
  - do NOT administer with NaHCO₃
  - repeat ECG consider further dose after 5 - 10 min if ECG changes present

- Insulin-Glucose IV infusion
  - Check pre-treatment blood glucose level
  - Give 10 units of regular insulin in 50 mL of 50% Glucose (25 g) via large IV access over 15-30 min
  - If pre-treatment blood glucose < 7.0 mmol/L, give 10% glucose @ 50 mL/hr for 5 hrs (25 g), monitor blood glucose level, titrate rate of infusion (see p.9)

- Consider: Salbutamol 10-20mg Nebulised

- Consider: Calcium resium
  - 15 g tds orally OR
  - 30 g bd per rectum
  - Always give with laxative (e.g. lactulose 15mL TDS)
  - Avoid in bowel obstruction/patient

- Sodium zirconium cyclosilicate (Lokelma)
  - 10 g tds for up to 72 hrs
  - dilute 10 g in 45 mL of water
  - do not use fruit juice which is high in potassium

- Consider: Diuretics
  - only if fluid overloaded
  - high doses (up to 250 mg of IV furosemide) may be needed in renal failure

- Consider: Sodium bicarbonate IV 1.26%
  - rate/volume determined by fluid status
  - only if hypokalaemic with a metabolic acidosis
  - risk of fluid overload / hypernatraemia, for cautions refer to page 10

- Consider: IV fluid therapy in pre-renal AKI

- Monitor U&Es and blood glucose, consider cause / prevent risk of recurrence

- Consider: haemodialysis-discuss with renal team (if pt is haemodynamically unstable, discuss with ITU for inotropic support & haemofiltration)
2. **Objective/s**

To improve the management of hyperkalaemia in adult patients (18 years or over) in the Trust.

3. **Scope**

Treatment of hyperkalaemic cardiac arrest is outside the scope of this guideline, the relevant algorithms and guidelines should be followed.

4. **Rationale**

Hyperkalaemia is a life-threatening condition, primarily due to its effect on the heart. It is defined as a serum potassium level higher than 5.5 mmol/L. It is seen in 1.1% to 10% of all hospitalised patients, with approximately 1% having significant hyperkalaemia of greater than 6.0 mmol/L and is associated with a high mortality rate (14.3% to 41%).

In most patients, the pathophysiology of hyperkalaemia is multifactorial, with reduced renal function, medications, acidosis, and hyperglycaemia being the most common contributing factors.

5. **Causes of hyperkalaemia**

5.1 **Pseudohyperkalaemia**

This is an artefactual increase in serum K⁺ due to its release from cells during or after venepuncture. Potential causes include:

- Increased K⁺ efflux from local muscle due to fist clenching or prolonged tourniquet time.
- Thrombocytosis, leucocytosis and/or erythrocytosis
- Delay in processing of sample leading to cell lysis

5.2 **Excessive potassium intake**

This is usually only a problem if potassium excretion is impaired, e.g. in patients with renal failure, those with a type IV renal tubular acidosis (e.g. diabetic nephropathy), or patients on drugs such as potassium-sparing diuretics, ACE inhibitors, or angiotensin receptor blockers, renin inhibitors.

Red cell transfusion is a well-described cause of hyperkalaemia, typically seen in children or in massive transfusions, but also in patients with significant renal dysfunction. Risk factors for transfusion-related hyperkalaemia include the rate and volume of transfusion, the use of central venous infusion and/or pressure pumping, the use of irradiated blood, and the age of the blood infused.

It is worth noting that some commonly used laxatives contain potassium – Movicol®, Laxido®, Klean-Prep® and Fybogel®.
Lo-Salt is a commercial preparation containing 66% potassium chloride (KCl). Patients with or at risk of hyperkalaemia should be advised not to use this as a salt substitute. Some herbal medicines (e.g. alfalfa, dandelion, horsetail, milk weed, nettle and others) also contain potassium and should be avoided in patients with or at risk of hyperkalaemia.

5.3 Re-distribution

Several different mechanisms can result in an efflux of intracellular potassium, resulting in hyperkalaemia:

- Increased serum osmolarity as in people with diabetes with severe hyperglycaemia or as a result of hypertonic mannitol.
- Rhabdomyolysis may cause hyperkalaemia.
- Metabolic acidosis associated with inorganic ions is associated with hyperkalaemia. Acidosis causes extracellular movement of K⁺: this is more profound with ‘fixed’ rather than organic acidosis.
- Digoxin inhibits Na⁺/K⁺-ATPase and therefore impairs uptake of potassium by skeletal muscle; thus digoxin overdose can result in hyperkalaemia.
- Non-selective β-blockers can cause hyperkalaemia in part by inhibiting cellular uptake (but also through effects on renin-aldosterone system)
- Agents that depolarise skeletal muscle, such as succinylcholine, or that activate potassium-dependent amino acid exchangers, such as lysine or arginine, can also lead to hyperkalaemia.

5.4 Impaired renal potassium excretion

Renal failure of any cause will usually lead to impaired potassium excretion.

Hypoaldosteronism will result in hyperkalaemia. Aldosterone promotes both kaliuresis and proton excretion in the cortical and medullary collecting ducts by a variety of mechanisms. Aldosterone deficiency or resistance (e.g. Addison’s disease, pseudohypoaldosteronism, type IV renal tubular acidosis) will therefore result in hyperkalaemia.

Several drugs cause impaired renal potassium excretion.

<table>
<thead>
<tr>
<th>Class</th>
<th>Examples</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE inhibitors</td>
<td>Lisinopril, ramipril, perindopril</td>
<td>Inhibit conversion of angiotensin I to angiotensin II</td>
</tr>
<tr>
<td>Angiotensin receptor blockers</td>
<td>Losartan, candesartan, irbesartan</td>
<td>Inhibit activation of angiotensin receptor by angiotensin II</td>
</tr>
<tr>
<td>Aldosterone receptor antagonists</td>
<td>Spironolactone, eplerenone, drospirenone</td>
<td>Block aldosterone receptor activation</td>
</tr>
</tbody>
</table>

Clinical Guideline for the Management of Hyperkalaemia in Adults

Author/s: Dr R Varma, Nicola Korn
Approved by: Chair of CGAP
Review date: 02/08/2024
Version: 5
Trust Docs ID: 9078
Clinical Guideline for the Management of Hyperkalaemia in Adults

<table>
<thead>
<tr>
<th>Potassium-sparing diuretics</th>
<th>Amiloride, triamterene (trimethoprim, co-trimoxazole and pentamidine are structurally similar to amiloride and can have similar effect)</th>
<th>Block/inhibit collecting duct apical Na⁺-Cl⁻ symport channels, decreasing gradient for potassium secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSAIDs</td>
<td>Ibuprofen, diclofenac</td>
<td>Inhibit prostaglandin stimulation of collecting duct potassium secretion, inhibit renin release, can cause renal failure</td>
</tr>
<tr>
<td>Calcineurin inhibitors</td>
<td>Cyclosporin, tacrolimus</td>
<td>Inhibit basolateral Na⁺/K⁺-ATPase in collecting duct; also inhibit apical secretory potassium channels</td>
</tr>
<tr>
<td>Heparin and LMWH</td>
<td>Heparin sodium, dalteparin, enoxaparin</td>
<td>Inhibit aldosterone synthase, rate-limiting enzyme for aldosterone synthesis</td>
</tr>
</tbody>
</table>

6. Processes to be followed

6.1 Broad recommendations

Management of hyperkalaemia is dictated by the potassium level and the severity of ECG changes. There is an overlap between conservative (see later) and emergency treatment of hyperkalaemia. For patients presenting with cardiac arrest – please follow ALS algorithm and relevant guidelines, medical treatment for hyperkalaemia should be given as per hyperkalaemic cardiac arrest algorithm.

Emergency treatment is indicated if:

- There is severe hyperkalaemia (K⁺ > 6.5 mmol/L)
- There are hyperkalaemic ECG changes – loss of P waves, prolonged PR interval, peaked T waves, widened QRS complexes, and sine wave development (hyperkalaemia may also be associated with bradycardia or complete heart block – in this situation, a temporary pacing wire and urgent dialysis is often necessary)

In situations where artefactual hyperkalaemia is a possibility, repeat U&Es should be taken, but do not delay treatment whilst waiting for result if any of the above are present.

Urgent management of hyperkalaemia is considered in three steps:

**STEP 1:** Antagonism of the cardiac effects of hyperkalaemia

**STEP 2:** Rapid reduction in serum potassium by redistribution into cells

**STEP 3:** Removal of potassium from the body
Note 1: It is mandatory that all patients with hyperkalaemia (K level ≥6.0 mmol/L) should have an urgent 12-lead ECG performed and, if there are any hyperkalaemic changes or if K level ≥ 6.5 mmol/L, should be on a cardiac monitor (minimum 3-lead continuous ECG monitoring).

Note 2: It is recommended that serum potassium is assessed at least 1, 2, 4, 6 and 24 hours after identification and treatment of moderate or severe hyperkalaemia.

Note 3: The following therapies are listed to explain the physiology and posology. A recommendation for a hierarchy of use is as per the attached algorithm.

Note 4: Some therapies are essentially holding-manoeuvres (Calcium, glucose/insulin, and salbutamol). In the absence of another treatable pathology (e.g. overt dehydration), definitive therapy – dialysis – will be necessary.

6.2  STEP 1: Antagonism of cardiac effects:

6.2.1  Calcium

Calcium reduces myocardial excitability in the face of hyperkalaemia. It is available as 10% calcium gluconate. The dose is 30 mL of 10% of calcium gluconate, administered intravenously over 10 minutes via large IV access with continuous cardiac monitoring. The effect is seen within 3 minutes and lasts 30-60 minutes. The dose may be repeated – after 5 to 10 minutes – if no effect is seen or if ECG changes recur after initial improvement. It MUST NOT be administered via a line containing bicarbonate as it will precipitate as calcium carbonate.

As an alternative to 10% calcium gluconate, 10% calcium chloride may be administered. The dose of 10% calcium chloride is 10 mL as it contains 3 times more calcium than calcium gluconate. Calcium chloride has been recommended in the setting of haemodynamic instability, including cardiac arrest.

Calcium should be used cautiously in patients taking digoxin as hypercalcaemia potentiates the action of digoxin and may precipitate myocardial toxicity. In this case, it is necessary to infuse it more slowly (over 30 min in 100 mL of 5% glucose) to allow for an even distribution of calcium in the extracellular compartment.

6.3  STEP 2: Redistribution of potassium into cells

6.3.1  Insulin and Glucose (off label use)

Insulin lowers serum potassium by stimulation of the Na⁺/K⁺-ATPase. This effect is reliable, reproducible, dose-dependent and effective.

In recent years, there have been multiple published reports on a high incidence of iatrogenic hypoglycaemia after administration of insulin and glucose. The most consistent risk factor for iatrogenic hypoglycaemia is a low pre-treatment blood glucose. Reducing the dose of insulin alone did not consistently reduce hypoglycaemic episodes, there is more evidence to support increasing the total glucose load to 50g. The lowest risk of severe hypoglycaemia was associated with continuous delivery of glucose. The
Clinical Guideline for the Management of Hyperkalaemia in Adults

treatment regimen has been altered to reduce the incidence of iatrogenic hypoglycaemia.

The recommended treatment regimen is:

- Check pre-treatment blood glucose level prior to insulin and glucose administration

- **Administer 10 units of actrapid insulin** (using an insulin syringe) with **50 mL of 50% glucose (25 g of glucose)**. This should be administered intravenously via a central venous access device/large vein via a syringe pump over 15-30 minutes. Monitor for phlebitis if 50% glucose is administered via a large peripheral vein.

  (NB-for alternative glucose regimens see box below)

- **If pre-treatment blood glucose < 7.0 mmol/L administer 10% glucose at 50 mL/hour for 5 hours (25 g)**
  - target blood glucose 4.0 – 7.0 mmol/L
  - titrate rate of infusion if required

- Monitor blood glucose as per advice below

- Anticipate and treat hypoglycaemia promptly

---

**Alternative Glucose regimens providing 25 g of glucose include 125 mL of 20% glucose or 250 mL of 10% glucose. The 10 units of soluble insulin should be added to the total volume of glucose required and drawn up into 50 mL intravenous syringes (syringe pump maximum volume is 50 mL). If alternative glucose regimens are used the syringe pump will need to be changed promptly several times through treatment.**

---

The effect on serum potassium begins in 10-20 minutes, peaks at 30-60 min, and lasts for 4-6 hours. In most patients, the serum potassium drops by 0.5-1.2 mmol/L with this treatment. The dose may be repeated if necessary.

Close monitoring of capillary blood glucose levels, for a minimum of 12 hours after administration of the insulin-glucose infusion, should be done at 0, 30, 60, 90, 120, 180, 240, 300, and 360, 480 and 720 minutes. If the patient has been started on a continuous glucose infusion titrate rate of infusion according to blood glucose levels.

Seek advice from senior medical doctor if patient becomes hypoglycaemic (capillary blood glucose < 4 mmol/L). If patient becomes hyperglycaemic whilst on 10% glucose infusion stop infusion and contact senior medical doctor for advice.

In hyperglycaemic patients with hyperkalaemia, insulin may be administered without glucose (in the case of diabetic ketoacidosis as a fixed rate insulin infusion) with close monitoring of serum glucose levels. Discuss with SpR or Consultant. For patients with diabetic ketoacidosis follow the national guideline for the management of adult patients with diabetic ketoacidosis. (Trust document ID: 1140)
6.3.2 β2-Adrenergic Agonists (Salbutamol) (off label use)
Salbutamol exerts its effects via activation of Na+/K+-ATPase.

The recommended dose is 10-20 mg of nebulised salbutamol. Its effects are seen at about 30 minutes and peak at 90 minutes, lasting for 2-6 hours. It reduces serum potassium levels by 0.5-1.0 mmol/L. However, several studies have shown that a subset of patients is not responsive to the potassium-lowering effects of salbutamol, and as such it should not be used as a single agent in the management of hyperkalaemia. The effects of salbutamol are also attenuated in patients on β-blockers and digoxin. It is unclear whether treatment with salbutamol has a significant additive effect to insulin on its own.

Treatment with salbutamol may cause a significant tachycardia and should be used in caution in those with ischaemic heart disease.

6.3.3 Sodium bicarbonate
Previously used routinely in the treatment of hyperkalaemia, sodium bicarbonate is now reserved for hyperkalaemia associated with renal failure and acidosis.

The recommended dose is 1.26% sodium bicarbonate infused intravenously at a rate determined by the patient’s fluid status and degree of acidosis.

Hyperkalaemia and metabolic acidosis with cardiac arrest should be treated with 50 mL of 8.4% sodium bicarbonate (which is available on the arrest trolley).

Sodium bicarbonate should be used with extreme caution in the following situations:

- In anuric or hypervolaemic patients – the significant sodium load may result in symptomatic fluid overload
- Hypocalcaemia – bicarbonate causes precipitation of calcium; the resultant fall in ionised calcium may result in tetany or fits
- Patients with type 2 respiratory failure – potential for paradoxical acidosis within the central nervous system

6.4 STEP 3: Removal of potassium from the body
6.4.1 Intravenous fluids
Most cases of acute (or acute on chronic) kidney injury in hospital are a result of intravascular volume depletion (i.e. pre-renal). In these situations, correction of volume status with intravenous fluids may be sufficient to restore renal function and promote a kaliuresis.

Compound sodium lactate (Hartmann’s solution) should not be used when hyperkalaemia is present as it contains 5 mmol/Litre of potassium.
6.4.2 Diuretics
In certain cases, increasing renal potassium elimination with diuretics may be adequate to lower total body potassium. However, in the setting of renal insufficiency (chronic or acute) the effectiveness of diuretic therapy may be limited. The use of diuretics is only indicated for those patients who are fluid replete.

In the acute setting, the diuretic most often used is intravenous furosemide. The dose will vary depending on renal function, but in those with significant renal impairment, up to 250 mg may be used to try and promote a kaliuresis: the effect is mild.

6.4.2.1 Sodium zirconium cyclosilicate
Sodium Zirconium Cyclosilicate (SZC) is a non-absorbed potassium binder that preferentially exchanges H⁺ and Na⁺ for K⁺ and ammonium ions throughout the entire gastrointestinal tract. The K⁺-binding capacity of SZC is up to 9 times greater than that of sodium polystyrenesulfonate. NICE has approved SZC as an option in the treatment of acute life-threatening hyperkalaemia alongside standard care in hospitalised patients.

Correction phase: the recommended dose is 10 g orally three times a day until normokalaemia (serum K 4.0-5.0 mmol/L) is achieved. Usual treatment duration is 24-48 hours, maximum duration is 72 hours. Sodium Zirconium Cyclosilicate should be discontinued after 72 hours if normokalaemia not achieved.

Maintenance phase: a dose of 5 g daily can be prescribed once normokalaemia is achieved, this can be titrated up to 10 g per day or down to 5 g alternate days depending on serum K levels. The maintenance dose should be discontinued once hypokalaemia develops (serum K level < 4.0 mmol/L)

The contents of the sachet should be emptied into a glass containing approximately 45 mL of water and stirred well. The powder will not dissolve. Advise the patient to drink the tasteless liquid while still cloudy, if the suspension settles it should be stirred again.

6.4.3 Cation-exchange resins
Ion-exchange resins are cross-linked polymers containing acidic or basic structural units that can exchange either anions or cations on contact with a solution. The most commonly used cation-exchange resin used is Calcium Resonium®. The onset of action is slow (> 4 hours) and efficacy is unpredictable therefore it should only be used in conjunction with other measures in the management of acute hyperkalaemia. It is also poorly tolerated due to taste and constipation. Cation exchange resins have been associated with colonic necrosis (most commonly seen with sodium polystyrene sulfonate used in conjunction with sorbitol). Therefore, they should not be used in those with bowel obstruction or an ileus.
The recommended dose is 15 g orally three times a day; each dose should be given with 15 mL of lactulose to prevent constipation and to facilitate passage of the resin through the gut.

Calcium Resonium® may also be administered rectally in those unable to take or tolerate it orally. The recommended dose is 30 g as an enema retained for 9 hours and followed by irrigation. (NB: For rectal administration please refer to summary of product characteristics, it can be administered rectally as a suspension of 30 g resin in 150 ml of water or 10% dextrose, as a daily retention enema.)

6.4.4 Extracorporeal potassium wasting – dialysis
All modes of renal replacement therapy are effective in removing potassium, with haemodialysis being the most rapid. Haemodialysis is indicated when hyperkalaemia is refractory to medical management.

If haemodialysis is likely to be necessary, it is important to enlist the help of the renal team at an early stage.

In patients who are haemodynamically unstable, haemodialysis may not be appropriate, and they may instead need haemofiltration – early consultation with the ITU team will be necessary.

6.4.5 Other measures
If a rapidly reversible cause of renal failure is identified, such as obstructive uropathy, then treatment of the underlying cause with close observation may be adequate to treat the hyperkalaemia.

All potentially offending drugs should be stopped immediately.

Although not indicated for acute hyperkalaemia, mineralocorticoid therapy (e.g. fludrocortisone starting at 50 microgram daily) may be indicated as chronic management of hyperkalaemia in patients with type IV renal tubular acidosis (e.g. diabetic nephropathy, sickle cell disease).

Patients with chronic renal failure and a chronic metabolic acidosis may benefit from long-term oral sodium bicarbonate (usually started at 500mg TDS) for chronic management of hyperkalaemia.

All patients should be placed on a low potassium diet. Patients have a sign "low potassium diet" added to beds/handover for catering to be alerted, not all patients remain on a low potassium diet once hyperkalaemia resolved hence it is not appropriate to give a leaflet to all patients. If renal fct doesn't improve and the patient remains under care of nephrology most patient will be seen by a renal dietician at some point (in particular if commencing renal replacement therapy); the available leaflets:

- Kidney Disease: Controlling your Potassium if you have Diabetes – Trust Doc ID 14863.
Clinical Guideline for the Management of Hyperkalaemia in Adults

- Kidney Disease - Controlling Your Potassium (Trust Doc ID: 107) will be handed out to relevant patients in a clinic environment/ by dieticians if appropriate

7. Clinical audit standards
This guideline is applicable across the Trust.

The renal clinical governance lead should coordinate a 3-yearly audit regarding the management of hyperkalaemia in (non-dialysis) patients with a [K+] >6.5 (identified via ICE). The audit will determine whether the management of patients with severe hyperkalaemia is in line with the treatment algorithm proposed in this guideline.

The audit results will be sent to the Clinical Standards Group and Effectiveness Sub-Board who will ensure that these are discussed at relevant governance meetings to review the results and make recommendations for further action.

8. Summary of development and consultation process undertaken before registration and dissemination

The authors listed above drafted this document, during its development it has been circulated for comment to: Dr M Karim, Dr M Mahdi Althaf Dr M Andrews, Dr A Friedla, Dr M Todd, Dr T Marshall, Ms H Willimott, Ms B Tedder.

This version has been endorsed by the Clinical Guidelines Assessment Panel.

9. References


10. **Equality Impact Assessment (EIA)**

Not applicable